|
|
Article: Availability and Use of Parenteral Quinidine Gluconate for Severe or Complicated Malaria.(recommendation for hospitals to improve their stocking of quinidine gluconate)(quinidine gluconate)(Brief Article)
- Article from:
- MMWR. Morbidity and Mortality Weekly Report
- Article date:
- December 22, 2000
CopyrightCOPYRIGHT 2000 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Since 1991, quinidine gluconate, a class la anti-arrhythmic agent, has been the only parenteral antimalarial available for use in the United States [1]. It is indicated for the treatment of patients with life-threatening Plasmodium falciparum malaria [2], including those who cannot tolerate oral therapy, have high-grade parasitemia, or have complications (e.g., cerebral malaria or acute renal failure) [3,4].
The limited availability of and delays in obtaining quinidine gluconate have contributed to adverse patient outcomes [5-7]. As newer anti-arrhythmics have replaced quinidine for many cardiac indications, some hospitals and other health-care facilities have ...